10 July 2019
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen…
9 July 2019
intu Derby Joint Venture Completion…
Half Year Trading Update
Directorate Change
Harworth grows income portfolio and commercial land pipeline…
AGM Statement
8 July 2019
Imperial Brands Announces Revised Capital Allocation and Shareholder Distributions Policy…
5 July 2019
Update on Proposals